wr 1065 has been researched along with EHS Tumor in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, KL; Coleman, MC; Grdina, DJ; Kataoka, Y; Kunnavakkam, R; Murley, JS; Spitz, DR | 1 |
| Grdina, DJ; Hunter, N; Kataoka, Y; Milas, L; Murley, JS; Weichselbaum, RR | 1 |
| Grdina, DJ; Kataoka, Y; Murley, JS; Oberley, LW; Weydert, CJ | 1 |
3 other study(ies) available for wr 1065 and EHS Tumor
| Article | Year |
|---|---|
Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.
Topics: Amifostine; Animals; Catalase; Female; Glutathione Peroxidase; Liver; Lung; Mercaptoethylamines; Mice; Mice, Inbred C3H; Myocardium; Pancreas; Radiation Tolerance; Radiation-Protective Agents; Sarcoma, Experimental; Superoxide Dismutase | 2009 |
Inhibition of spontaneous metastases formation by amifostine.
Topics: Amifostine; Angiostatins; Animals; Blotting, Western; Cell Division; Dose-Response Relationship, Drug; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mercaptoethylamines; Mice; Mice, Inbred C3H; Muscle Neoplasms; Neoplasm Invasiveness; Peptide Fragments; Plasminogen; Radiation-Protective Agents; Sarcoma, Experimental; Xenograft Model Antitumor Assays | 2002 |
Delayed cytoprotection after enhancement of Sod2 (MnSOD) gene expression in SA-NH mouse sarcoma cells exposed to WR-1065, the active metabolite of amifostine.
Topics: Animals; Cell Survival; Electrophoresis, Polyacrylamide Gel; Gene Expression Regulation, Enzymologic; Mercaptoethylamines; Mice; Radiation-Protective Agents; Sarcoma, Experimental; Superoxide Dismutase; Tumor Cells, Cultured; X-Rays | 2002 |